MedTrace Logo

Diabetes and Palliative Care

NCT02742701 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 180

Last updated 2016-04-19

No results posted yet for this study

Summary

Diabetes prevalence in palliative care is 10-15%. Most hospice patients are treated with insulin. The target glucose level is high in order to decrease the risk of hypoglycemia. Glucose level is usually monitored using capillary blood glucose once to three times daily.

The aim of the research is to simplify this pattern of care in end-of-life patients. It will evaluate whether the non invasive measurement of glucose in urine could replace the measurement of capillary blood glucose. The first objective will be to assess the performance of the measurement of glucosuria using urinary dip stix to predict that the blood glucose level is within the target range.

Due to the high glucose target, hyperglycemia is extremely frequent. However, symptoms of hyperglycemia are unfrequently reported. They may be unspecific and/or masked in end-of-life patients due to terminal disease and medication. The second objective of the study will be to define symptoms of hyperglycemia in these patients.

Conditions

Interventions

OTHER

diagnosis

Measurement of glycosuria

Sponsors & Collaborators

  • Maison Médicale Jeanne Garnier

    lead OTHER

Principal Investigators

  • Frederic Guirimand, MD · Pôle Recherche Maison Médicale Jeanne Garnier

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-04-30
Primary Completion
2017-10-31
Completion
2018-01-31

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02742701 on ClinicalTrials.gov